Good evening :)
Switch to
Place Order

Alkem Laboratories Ltd

ALKEM
Health CarePharmaceuticals
MidcapWith a market cap of ₹37,065 cr, stock is ranked 138
Low RiskStock is 1.24x as volatile as Nifty
3,068.351.02% (-31.65)
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
MidcapWith a market cap of ₹37,065 cr, stock is ranked 138
Low RiskStock is 1.24x as volatile as Nifty

Key Metrics

PE RatioPE RatioPB RatioPB RatioDividend YieldDiv. Yield
22.524.191.10%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
35.694.330.89%

Forecast & RatingsDetailed Forecast 

43%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Alkem Laboratories Limited is a pharmaceutical company. The Company is engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products. The Company operates through two segments: pharmaceutical and investing. The Company produces generics, generic drugs, active pharmaceutical ingredients (APIs) and neutraceuticals, which it markets in India and approximately 50 countries internationally, primarily the United States. The Company offers various products, such as CLAVAM 375, CLAVAM BID DRY SYRUP, CLAVAM INJ 300MG, FREEAIR NASAL SPRAY, PAN 40MG INJECTION (VIAL), PAN/40MG TABLETS, PROWEL DRY SYRUP (30ML), TAXCLAV 100 DT TABLETS, SATROGYL O DRY SYRUP, XONE/500MG VAIL, MEROSURE KIT 500, MEROSURE 500 MG and ZADONASE, among others. The Company has approximately 16 manufacturing facilities, of which 14 manufacturing facilities are at geographically diversified locations in India and two in the United States.

Brands

Alkem Labs

Pharmaceutical company

Investor PresentationView older 

Nov 11, 2022

PDF
View Older Presentations

Brands

Alkem Labs

Pharmaceutical company

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

2019202020212022+7.44+8.45+9.10+10.80+0.76+1.13+1.59+1.65
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Increased Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 1.57%

See detailed holdings

Recent EventsAll events 

Related Party Transaction 
Announced OnNov 25, 2022

Alkem Laboratories Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

Alkem Laboratories Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

Schedule of Analysts/Institutional Investor Meet/Con. Call 
Announced OnNov 23, 2022

Alkem Laboratories Limited has informed the Exchange about Schedule of Analysts/Institutional Investor Meet/Con. Call | Download

Alkem Laboratories Limited has informed the Exchange about Schedule of Analysts/Institutional Investor Meet/Con. Call | Download

Cash Dividend 
Ex. DateAug 8, 2022

Final • Div/Share: ₹ 4

See all events